GBA1 and Parkinson disease: The molecular mechanisms by which GBA mutations result in this increased risk are currently the focus of substantial research efforts. Studies using iPSC-derived midbrain DA neurons from PD patients harboring GBA N370S mutation showed a reduction in glucocerebrosidase (GCase) activity, increased α-synuclein levels and a reduced capacity to synthesize and release dopamine8.